Alchemab Secures £25M Series A Extension, Fuels AI-Driven Antibody Pipeline
July 11, 2026, 9:32 am
Location: United Kingdom, England, Sheffield
Employees: 201-500
Founded date: 2014
Total raised: $8.95B
Location: United Kingdom
Employees: 11-50
Founded date: 2019
Total raised: $148.59M
Alchemab Therapeutics landed a substantial £25M Series A extension. The British Business Bank led this pivotal investment. It pushes Alchemab's total Series A funding to an impressive £109M. This capital injection accelerates the Cambridge, UK-based biotech's ambitious plans. Alchemab leverages its unique AI-powered Resiliome platform. The platform identifies protective antibodies from individuals resilient to tough diseases. The new funds will rapidly expand its proprietary antibody database. It will grow from 500 million to over one billion sequences. This expansion is critical for its advanced AI engine. The goal is to uncover first-in-class antibody therapeutics.
The funding also propels Alchemab’s clinical pipeline. Its lead candidate, ATLX-1282, targets amyotrophic lateral sclerosis (ALS). Eli Lilly licensed this asset, a strong validation of Alchemab's innovative approach. The company aims to move more novel antibody candidates into clinical trials faster. This investment marks the largest life sciences commitment by the British Business Bank to date. It highlights increasing confidence in the UK's burgeoning biotech sector. Alchemab’s strategy holds significant promise for patients suffering from conditions with high unmet medical needs. The company's unique blend of human biology and artificial intelligence positions it at the forefront of drug discovery.
Alchemab's core innovation lies in its Resiliome platform. This sophisticated system integrates extensive human antibody data. It focuses on individuals naturally resistant to specific diseases. Such individuals possess unique antibodies. These antibodies protect them from illness. Alchemab's platform deep sequences these antibodies. It then combines this data with advanced AI algorithms. This process identifies the most promising therapeutic candidates. The lab validates these discoveries. This approach offers a powerful alternative to traditional drug discovery methods. It directly taps into the body's natural defenses.
The expanded antibody database is a cornerstone of Alchemab's strategy. Growing it to over a billion sequences provides an unparalleled resource. This massive dataset feeds its AI engine. The more data the AI processes, the smarter and more efficient it becomes. This allows for faster identification of novel drug targets. It also enables quicker development of potential treatments. The company's proprietary data advantage is a significant differentiator in the competitive biotech landscape. It underscores a commitment to data-driven innovation.
This latest investment validates Alchemab's scientific progress. It recognizes its commercial potential. Existing investors also supported the extension. These include SV Health Investors and the Dementia Discovery Fund. RA Capital, DCVC Bio, Eli Lilly, Lightstone Ventures, Ono Venture Investment, and Camford Partners are also key backers. Their continued commitment speaks volumes. It reflects strong belief in Alchemab's platform and leadership. Dr. Jane Osbourn, CEO, guides the company. Her vision drives its progress.
The British Business Bank's investment is strategic. It supports high-growth, innovative UK companies. The life sciences sector is a national priority. This funding helps Alchemab scale operations within the UK. It fosters domestic talent. It also contributes to the UK's reputation as a global biotech hub. The investment demonstrates a commitment to long-term capital for crucial scientific advancements. This is vital for complex drug pipelines.
Alchemab's focus on disease-resilient individuals is revolutionary. Many diseases lack effective treatments. Traditional drug discovery often struggles. It can miss subtle but powerful biological defenses. Alchemab bypasses these hurdles. It directly learns from human success stories. This could unlock therapies previously deemed impossible. It offers hope for devastating conditions. These include neurodegenerative disorders, autoimmune diseases, and chronic infections.
The partnership with Eli Lilly for ATLX-1282 is a significant milestone. It validates the Resiliome platform's ability. It can deliver clinically viable assets. ALS is a brutal neurodegenerative disease. There is a desperate need for effective therapies. ATLX-1282's progress into clinical development is promising. It shows the real-world impact of Alchemab's science. This collaboration provides an essential proof of concept. It boosts confidence in Alchemab's entire pipeline.
Alchemab aims to accelerate new antibody candidates. The additional capital makes this possible. It will move them faster into clinical trials. This means more potential therapies reaching patients sooner. The drug development process is lengthy and costly. Efficiency is paramount. Alchemab's AI-driven platform seeks to streamline this. It reduces risk and accelerates timelines. This delivers greater value to investors and patients alike.
The UK life sciences sector is experiencing robust growth. Companies like Alchemab lead this charge. They combine cutting-edge technology with deep scientific expertise. Alchemab exemplifies this strength. Its integration of deep sequencing, advanced AI, and lab validation is world-class. The company is building a globally significant biotech enterprise. This investment helps secure its future. It solidifies its place as an innovator.
The company was founded in 2019. In a short time, it has achieved substantial milestones. Its rapid Series A funding growth demonstrates strong investor confidence. Its unique platform offers a compelling value proposition. Alchemab is not just developing drugs. It is pioneering a new paradigm in drug discovery. It is unlocking the body's inherent power to heal. This future-focused approach promises to redefine therapeutic development for many years to come.
The funding also propels Alchemab’s clinical pipeline. Its lead candidate, ATLX-1282, targets amyotrophic lateral sclerosis (ALS). Eli Lilly licensed this asset, a strong validation of Alchemab's innovative approach. The company aims to move more novel antibody candidates into clinical trials faster. This investment marks the largest life sciences commitment by the British Business Bank to date. It highlights increasing confidence in the UK's burgeoning biotech sector. Alchemab’s strategy holds significant promise for patients suffering from conditions with high unmet medical needs. The company's unique blend of human biology and artificial intelligence positions it at the forefront of drug discovery.
Alchemab's core innovation lies in its Resiliome platform. This sophisticated system integrates extensive human antibody data. It focuses on individuals naturally resistant to specific diseases. Such individuals possess unique antibodies. These antibodies protect them from illness. Alchemab's platform deep sequences these antibodies. It then combines this data with advanced AI algorithms. This process identifies the most promising therapeutic candidates. The lab validates these discoveries. This approach offers a powerful alternative to traditional drug discovery methods. It directly taps into the body's natural defenses.
The expanded antibody database is a cornerstone of Alchemab's strategy. Growing it to over a billion sequences provides an unparalleled resource. This massive dataset feeds its AI engine. The more data the AI processes, the smarter and more efficient it becomes. This allows for faster identification of novel drug targets. It also enables quicker development of potential treatments. The company's proprietary data advantage is a significant differentiator in the competitive biotech landscape. It underscores a commitment to data-driven innovation.
This latest investment validates Alchemab's scientific progress. It recognizes its commercial potential. Existing investors also supported the extension. These include SV Health Investors and the Dementia Discovery Fund. RA Capital, DCVC Bio, Eli Lilly, Lightstone Ventures, Ono Venture Investment, and Camford Partners are also key backers. Their continued commitment speaks volumes. It reflects strong belief in Alchemab's platform and leadership. Dr. Jane Osbourn, CEO, guides the company. Her vision drives its progress.
The British Business Bank's investment is strategic. It supports high-growth, innovative UK companies. The life sciences sector is a national priority. This funding helps Alchemab scale operations within the UK. It fosters domestic talent. It also contributes to the UK's reputation as a global biotech hub. The investment demonstrates a commitment to long-term capital for crucial scientific advancements. This is vital for complex drug pipelines.
Alchemab's focus on disease-resilient individuals is revolutionary. Many diseases lack effective treatments. Traditional drug discovery often struggles. It can miss subtle but powerful biological defenses. Alchemab bypasses these hurdles. It directly learns from human success stories. This could unlock therapies previously deemed impossible. It offers hope for devastating conditions. These include neurodegenerative disorders, autoimmune diseases, and chronic infections.
The partnership with Eli Lilly for ATLX-1282 is a significant milestone. It validates the Resiliome platform's ability. It can deliver clinically viable assets. ALS is a brutal neurodegenerative disease. There is a desperate need for effective therapies. ATLX-1282's progress into clinical development is promising. It shows the real-world impact of Alchemab's science. This collaboration provides an essential proof of concept. It boosts confidence in Alchemab's entire pipeline.
Alchemab aims to accelerate new antibody candidates. The additional capital makes this possible. It will move them faster into clinical trials. This means more potential therapies reaching patients sooner. The drug development process is lengthy and costly. Efficiency is paramount. Alchemab's AI-driven platform seeks to streamline this. It reduces risk and accelerates timelines. This delivers greater value to investors and patients alike.
The UK life sciences sector is experiencing robust growth. Companies like Alchemab lead this charge. They combine cutting-edge technology with deep scientific expertise. Alchemab exemplifies this strength. Its integration of deep sequencing, advanced AI, and lab validation is world-class. The company is building a globally significant biotech enterprise. This investment helps secure its future. It solidifies its place as an innovator.
The company was founded in 2019. In a short time, it has achieved substantial milestones. Its rapid Series A funding growth demonstrates strong investor confidence. Its unique platform offers a compelling value proposition. Alchemab is not just developing drugs. It is pioneering a new paradigm in drug discovery. It is unlocking the body's inherent power to heal. This future-focused approach promises to redefine therapeutic development for many years to come.